Intact Fish Skin for Tissue Regeneration - Kerecis logo
Contact Us

Breakthrough Evidence Brings New Hope to Patients with Severe DFUs, Including Those with Exposed Bone or Tendon

Contact Us
Download the Evidence Summary
The largest RCT to date evaluating DFUs with exposed structure found that 66% more relative wounds healed at week 16 with Kerecis vs SOC — helping clinicians treat their most complex patients.

Backed by five randomized controlled trials and more than 100 peer-reviewed publications, Kerecis® MariGen® is FDA-cleared for use over bone and tendon—supporting provider confidence in documentation, clinical outcomes, and product selection in today’s evolving reimbursement landscape

Patients treated with Kerecis had a 1.6x greater chance of healing and healed nearly two weeks faster.
DFUs classified as University of Texas (UT) grades 2 and 3 are some of the most challenging wounds to treat, and are associated with higher rates of infection, delayed healing, and increased risk of amputation.1

The increased risk associated with grade 2 and 3 diabetic foot ulcers stems from their depth and complexity.

Increased Depth and Complexity creates:

  • Penetration down through the dermis and subcutaneous tissue
  • Depth creates environment for bacterial growth
  • Exposed structures avascular and with limited capability for fighting infection
  • Granulation tissue needs to migrate over exposed structures

For patients with University of Texas (UT) grade 2 and 3 ulcers – the severe cases where bone or tendon is exposed – the stakes of having an open wound are high:

  • Higher risk of infection2
  • Up to 80% increased risk of amputation3
  • Increased healthcare costs per patient4
  • 5-year mortality rates of up to 45%5

Kerecis understands that managing deep, complex DFUs can be difficult, especially when evidence-based options are limited. These wounds carry a significant burden for patients and their families, yet historically there has been little large-scale, randomized clinical data to help guide treatment decisions.
To help address this gap, the Odinn RCT was designed to evaluate healing outcomes in DFUs with exposed structures and provide clinicians with meaningful, comparative evidence.”

Statistically Significant Improvements in Deep DFU Healing

 

Significant Results: (95% CI: 1.48 – 4.56)

Read Publication

The Odinn trial represents true level 1 evidence that advanced therapeutics such as intact fish skin grafts make a difference in the real world of deep and complex diabetic foot wounds

Lantis
Dr. John Lantis
, MD
Site-Chief of Surgery at the Mount Sinai West Hospital, and study co-author.

Frequently Asked Questions

The Odinn study is a landmark study representing the first large-scale RCT focused exclusively on UT grade 2 and 3 DFUs, involving 255 patients across 15 centers. The scale and focus of this trial provide unprecedented insights into the management of these complex wounds, offering clinicians and patients a new level of evidence in an area where it has been lacking. By specifically targeting these severe ulcers, the study addresses a critical unmet need in diabetic foot care.

The primary funding sources were the European Commission Fast Track to Innovation Horizon 2020 (80%) and Kerecis Ltd. (13%).

The study focused on complex ulcers with a higher associated healthcare cost. The Odinn study was designed to show efficacy for Intact fish skin grafts in complex DFUs with exposed bone and tendon (UT 2 and 3). The study was designed to fulfill all the clinical trial criteria of the AHRQ evidence criteria for Skin substitutes in the USA and criteria of European insurance programs to offer reimbursement coverage.

Feel free to contact us

Access the Evidence

Confidently Manage DFUs with MariGen

As you evaluate advanced options for challenging DFUs, MariGen offers a biologically rich, intact fish-skin graft designed to support healing in deep, complex wounds.
The MariGen product line includes multiple variations and sizes to meet diverse DFU needs and is indicated for full-thickness wounds extending through the dermis to deeper tissues— including subcutaneous fat, muscle, bone, and tendon.

This allows care providers to confidently manage DFUs with exposed structures using a solution backed by growing clinical evidence.

 

Need more information?

Contact Us
From the town of Isafjordur in northwest Iceland, Kerecis develops, manufactures, and sells patented fish skin soft tissue regeneration products that have regulatory approval in the United States, Europe and several other jurisdictions.
References
1

Prevalence of diabetes, diabetic foot ulcer, and lower extremity amputation among Medicare beneficiaries, 2006-2008.. Content last reviewed December 2019. Effective Health Care Program, Agency for Healthcare Research and Quality, Rockville, MD.

2

Armstrong, D. G., Boulton, A. J., & Bus, S. A. (2017). Diabetic foot ulcers and their recurrence. New England Journal of Medicine, 376(24), 2367-2375.

3

Lavery, L. A., Armstrong, D. G., & Harkless, L. B. (1996). Classification of diabetic foot wounds. The Journal of Foot and Ankle Surgery, 35(6), 528-531.

4

Rice, J. B., Desai, U., Cummings, A. K., Birnbaum, H. G., Skornicki, M., & Parsons, N. B. (2014). Burden of diabetic foot ulcers for Medicare and private insurers. Diabetes Care, 37(3), 651-658.

5

Moulik, P. K., Mtonga, R., & Gill, G. V. (2003). Amputation and mortality in new-onset diabetic foot ulcers stratified by etiology. Diabetes Care, 26(2), 491-494.

© 2010 – 2025 Kerecis. All Rights Reserved